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Summary
Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden 
and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus surgery. 
Dupilumab is a fully human monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13, key drivers of 
type 2 inflammation, and has been approved for use in atopic dermatitis and asthma. In these two studies, we aimed 
to assess eﬃcacy and safety of dupilumab in patients with CRSwNP despite previous treatment with systemic 
corticosteroids, surgery, or both.
Methods LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 were two multinational, multicentre, randomised, 
double-blind, placebo-controlled, parallel-group studies assessing dupilumab added to standard of care in adults 
with severe CRSwNP. SINUS-24 was done in 67 centres in 13 countries, and SINUS-52 was done in 117 centres in 
14 countries. Eligible patients were 18 years or older with bilateral CRSwNP and symptoms despite intranasal 
corticosteroid use, receiving systemic corticosteroids in the preceding 2 years, or having had sinonasal surgery. 
Patients in SINUS-24 were randomly assigned (1:1) to subcutaneous dupilumab 300 mg or placebo every 2 weeks for 
24 weeks. Patients in SINUS-52 were randomly assigned (1:1:1) to dupilumab 300 mg every 2 weeks for 52 weeks, 
dupilumab every 2 weeks for 24 weeks and then every 4 weeks for the remaining 28 weeks, or placebo every 2 weeks 
for 52 weeks. All patients were randomly assigned centrally with a permuted block randomisation schedule. 
Randomisation was stratified by asthma or non-steroidal anti-inflammatory drug-exacerbated respiratory disease 
status at screening, previous surgery at screening, and country. Patients with or without comorbid asthma were 
included. Coprimary endpoints were changes from baseline to week 24 in nasal polyp score (NPS), nasal congestion 
or obstruction, and sinus Lund-Mackay CT scores (a coprimary endpoint in Japan), done in an intention-to-treat 
population. Safety was assessed in a pooled population of both dupilumab groups in SINUS-52 up to week 24 and 
the dupilumab group in SINUS-24 and the placebo groups in both studies until week 24. The trials are complete 
and registered at ClinicalTrials.gov, NCT02912468 and NCT02898454.
Findings Between Dec 5, 2016, and Aug 3, 2017, 276 patients were enrolled in SINUS-24, with 143 in the dupilumab 
group and 133 in the placebo group receiving at least one study drug dose. Between Nov 28, 2016, and Aug 28, 2017, 
448 patients were enrolled in SINUS-52, with 150 receiving at least one dose of dupilumab every 2 weeks, 
145 receiving at least one dose of dupilumab every 2 weeks for 24 weeks and every 4 weeks until week 52, 
and 153 receiving at least one dose of placebo. Dupilumab significantly improved the coprimary endpoints in both 
studies. At 24 weeks, least squares mean diﬀerence in NPS of dupilumab treatment versus placebo was –2·06 (95% CI 
–2·43 to –1·69; p<0·0001) in SINUS-24 and –1·80 (–2·10 to –1·51; p<0·0001) in SINUS-52; diﬀerence in nasal 
congestion or obstruction score was −0·89 (–1·07 to –0·71; p<0·0001) in SINUS-24 and −0·87 (–1·03 to –0·71; 
p<0·0001) in SINUS-52; and diﬀerence in Lund-Mackay CT scores was –7·44 (–8·35 to –6·53; p<0·0001) in 
SINUS-24 and –5·13 (–5·80 to –4·46; p<0·0001) in SINUS-52. The most common adverse events (nasopharyngitis, 
worsening of nasal polyps and asthma, headache, epistaxis, and injection-site erythema) were more frequent with 
placebo.
Interpretation In adult patients with severe CRSwNP, dupilumab reduced polyp size, sinus opacification, and 
severity of symptoms and was well tolerated. These results support the benefits of adding dupilumab to daily 
standard of care for patients with severe CRSwNP who otherwise have few therapeutic options.
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Introduction
Chronic rhinosinusitis with nasal polyps (CRSwNP), 
an important phenotype of chronic rhinosinusitis,1,2 
has an estimated prevalence of 4·2% in the USA and 
4·3% in Europe.3,4 The clinical, economic, and human 
burden of this condition is poorly recognised despite the 
high symptom burden, troublesome and diﬃcult-to-
treat loss of smell,5–7 high rates of recurrence or relapse 
of nasal polyps after surgery, frequent comorbid late-
onset asthma, and poor health-related quality of life.8 
CRSwNP predominantly displays type 2 inflam matory 
signatures including interleukin (IL)-4, IL-5, and IL-13, 
and infiltration of nasal polyps by eosinophils, basophils, 
and mast cells.9,10 Non-steroidal anti-inflam matory drug 
(NSAID)-exacerbated respiratory disease (also termed 
Samter’s triad, aspirin-exacerbated respi ratory disease 
in the USA, or N-exacerbated respiratory disease in 
Europe) is a disease phenotype described as aspirin or 
NSAID hypersensitivity, asthma, and CRSwNP and is 
associated with a type 2 inflammatory reaction. Asthma 
and NSAID-exacerbated respiratory disease are frequent 
type 2 inflammatory comorbidities, with asthma occur-
ring in up to 65% and NSAID-exacerbated respiratory 
disease occurring in up to 16% of patients with 
CRSwNP.11–14 Patients with CRSwNP and comorbid 
asthma (with and without NSAID-exacerbated respira-
tory disease) have more severe disease, charac terised by 
high nasal polyp scores, recurrence of nasal polyps after 
surgery, frequent systemic corticosteroid dependence, 
poor asthma control, and higher costs and use of health-
care resources.15
Novel therapies to improve disease control are needed to 
spare patients from systemic corticosteroids and repeated 
sinus surgery. Current standard-of-care options for 
CRSwNP1,2 have limitations. Intranasal corticosteroids are 
the first line of therapy but have small eﬀects on polyp 
size and symptoms. When symptoms worsen, systemic 
corticosteroids provide short-term eﬃcacy,16 but adverse 
eﬀects prevent long-term use. When pharmacological 
therapy is unsuccessful, surgery can be eﬀective but, 
without control of the underlying inflammation disease, 
recurrence is common,17 resulting in repeated courses of 
systemic corticosteroids and surgery in a subgroup of 
patients with nasal polyps. A therapy that directly targets 
the fundamental type 2 inflammation driving this disease 
might provide the opportunity to oﬀer an eﬀective and well 
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Research in context
Evidence before this study
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a 
predominantly type 2 inflammation-mediated disease with 
high disease burden and poor quality of life. In a subgroup 
of patients with CRSwNP and severe type 2 inflammation, 
typically associated with comorbid late-onset asthma and 
disease recurrence after surgical therapy, disease control 
cannot be achieved by existing standard of care. We searched 
MEDLINE (via PubMed) and Embase for articles from database 
inception up to Aug 4, 2016, using search terms including 
“nasal polyposis”, “chronic rhinosinusitis”, “chronic 
rhinosinusitis with nasal polyps”, “AERD”, “NSAID-ERD”, 
“Samter’s”. Additionally, we used the Cochrane Library to 
search other databases, including the Cochrane Central Library 
of Controlled Trials. Grey literature and other resources were 
hand-searched to identify any other relevant data. We did a 
claims-database analysis to ascertain the treatment patterns 
and cost burden of CRSwNP in the USA. We did extensive 
analyses on the disease using the GALEN sinusitis cohort of 
patients with chronic rhinosinusitis in Europe. Dupilumab has 
been shown to have significant eﬃcacy in diseases driven by 
type 2 inflammation, such as moderate-to-severe atopic 
dermatitis and moderate-to-severe asthma in patients aged 
12 years or older. In a previous phase 2, proof-of-concept study 
in patients with CRSwNP, dupilumab showed significant 
eﬃcacy in reducing nasal polyp burden and was well tolerated.
Added value of this study
To our knowledge, LIBERTY NP SINUS-24 and LIBERTY NP 
SINUS-52 are the first and largest phase 3 trials to date assessing 
a monoclonal antibody targeting this type 2 inflammatory 
condition, investigating dupilumab eﬃcacy as an add-on 
treatment to standard intranasal corticosteroids in patients 
with severe uncontrolled CRSwNP. In both studies, 
dupilumab reduced nasal polyp size and sinus disease burden, 
reduced severity of symptoms, improved sense of smell, improved 
health-related quality of life, and reduced the use of systemic 
corticosteroids and the need for nasal polyp surgery. In patients 
with comorbid asthma, dupilumab also improved lung function 
and asthma control. Dupilumab was shown to be well tolerated.
Implications of all the available evidence
Existing therapies for CRSwNP have limitations and do not 
address the underlying type 2 inflammatory processes that 
drive this disease with frequent recurrence. Blocking 
interleukin (IL)-4 and IL-13 signalling with dupilumab, 
in addition to the use of intranasal corticosteroids, 
could improve the lives of patients with severe uncontrolled 
CRSwNP compared with standard of care. Dupilumab 
treatment also showed eﬃcacy in treating patients with 
comorbid asthma, a patient population with an increased 
disease burden that is diﬃcult to treat.
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tolerated option that also addresses common comorbid, 
substantial type 2 inflammatory diseases such as asthma.
Dupilumab is a fully human VelocImmune-derived 
monoclonal antibody18,19 that inhibits signalling by IL-4 and 
IL-13, cytokines that are key drivers of type 2 inflammation.20 
This antibody has been approved by the US Food and 
Drug Administration as an add-on maintenance treatment 
in adult patients with inadequately controlled CRSwNP. 
Dupilumab has also been approved for the treatment of 
other type 2 inflammatory disorders, including in patients 
aged 12 years or older in the USA with moderate-to-severe 
atopic dermatitis inadequately controlled with topical 
prescription therapies, or for whom those therapies are not 
advisable; in adults with inadequately controlled moderate-
to-severe atopic derma titis who are candidates for systemic 
therapy in the EU and other countries;21–23 in patients aged 
12 years or older in Japan as add-on maintenance treat-
ment for moderate-to-severe asthma with an eosinophilic 
phenotype, or oral corticosteroid-dependent asthma, and 
for severe or refractory asthma with symptoms that are 
inadequately controlled with existing therapy; and in 
patients with type 2 severe asthma characterised by 
increased blood eosinophils, raised fractional exhaled 
nitric oxide, or both, who are inadequately controlled with 
high-dose inhaled cortico steroids plus another medicinal 
product for maintenance treatment in the EU.24–26
In these two phase 3 trials, LIBERTY NP SINUS-24 
and LIBERTY NP SINUS-52, we aimed to assess the 
eﬃcacy and safety of dupilumab when added to standard 
therapy (intranasal corticosteroids) in adults with severe 
CRSwNP uncontrolled by standard of care, including 
patients with a history of comorbid asthma, NSAID-
exacerbated respiratory disease, or both.
Methods
Study design
LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 
were two multinational, multicentre, randomised, double-
blind, placebo-controlled, parallel-group studies assessing 
the eﬃcacy and safety of dupilumab in patients with severe 
uncontrolled CRSwNP. SINUS-24 was done in 67 hospitals 
or clinical centres in 13 countries (Bulgaria, Czechia, 
France, Germany, Hungary, Italy, the Netherlands, Poland, 
Romania, Ukraine, Russia, the UK, and the USA). 
SINUS-52 was done in 117 hos pitals or clinical centres 
in 14 countries (Argentina, Australia, Belgium, Canada, 
Chile, Israel, Mexico, Portugal, Russia, Spain, Sweden, 
Turkey, Japan, and the USA). Details of the study designs 
and multiplicity-controlled testing hierarchy are presented 
in the appendix (pp 11–12). The trials consisted of a 4-week 
run-in period, a treatment period (24 weeks in SINUS-24 
and 52 weeks in SINUS-52), and a follow-up period 
(24 weeks in SINUS-24 and 12 weeks in SINUS-52). The 
protocols were developed by the sponsors in collaboration 
with the principal investigators. The local institutional 
review board or ethics committee at each study centre 
oversaw trial conduct and documentation.
Patients
Eligibility criteria were the same for both studies 
(appendix pp 7–8). Eligible patients were aged 18 years 
or older with bilateral nasal polyps and symptoms of 
chronic rhinosinusitis despite intranasal corticosteroid 
therapy before randomisation and had received systemic 
corticosteroids in the preceding 2 years (or had a medical 
contraindication or intolerance to systemic cortico-
steroids) or previous sinonasal surgery. At screening, 
patients were required to have a bilateral endoscopic nasal 
polyp score (NPS) of at least 5 (maximum 8), with 
a minimum score of 2 for each nostril, and exhibit at least 
two of the following symptoms: nasal congestion or 
obstruction (patient-assessed symptom severity score of at 
least 2 of 3, and a weekly average score of at least 1 at 
randomisation; 0=no symptoms, 1=mild, 2=moderate, 
and 3=severe) and either loss of smell or nasal discharge 
(anterior or posterior). These criteria resulted in a study 
population with severe disease. A prespecified enrolment 
goal of 50% of patients with asthma, NSAID-exacerbated 
respiratory disease, or both on the basis of patient-reported 
history and 50% of patients having had previous surgery 
was met without the need to cap enrolment. Patients 
who had a forced expiratory volume in 1 second (FEV₁) of 
50% or lower than the predicted normal or participated in 
other dupilumab studies were excluded. Other key 
exclusion criteria are detailed in the appendix (p 8).
Saline nasal lavage, systemic antibiotics, short-course 
systemic corticosteroids, or sinonasal surgery were per-
mitted as needed during the treatment and follow-up 
periods. All patients provided written informed consent 
before participating in the trials.
Randomisation and masking
In SINUS-24, patients were randomly assigned (1:1) to 
dupilumab 300 mg every 2 weeks or to matching placebo. 
In SINUS-52, patients were randomly assigned (1:1:1) to 
dupilumab 300 mg every 2 weeks for 52 weeks (group A), 
the same schedule for the first 24 weeks followed by 
dupilumab 300 mg every 4 weeks (group B), or placebo 
(group C).
Patients were randomly assigned centrally with a 
permuted block randomisation schedule by Interactive 
Voice Response System or Interactive Web Response 
System. Randomisations and allocations were done with 
use of ClinPhone from Parexel (Waltham, MA, USA), 
which generated the patient randomisation list and treat-
ment assignment. Site personnel had access to the portal, 
did interactive response technology calls, and received 
corresponding notifications from ClinPhone. The ran-
domisation block size was four for SINUS-24 and six for 
SINUS-52. Randomisation was stratified by asthma or 
NSAID-exacerbated respiratory disease status at screening 
(visit 1), previous surgery at screening, and country. 
The sponsor provided the randomisation scheme to the 
centralised treatment allocation system and treatments 
were allocated to the patients accordingly. Both patients 
See Online for appendix
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and investigators were masked to the assigned drug, with 
active drug or matching placebo used in identical prefilled 
syringes labelled with a treatment kit number. Treatment 
group information was masked in data transfers from 
Parexel to the sponsor until database lock.
Procedures
During the 4-week run-in period and throughout the trial, 
patients received 100 µg of mometasone furoate nasal spray 
(MFNS) in each nostril twice daily. Afterwards, patients 
in SINUS-24 received either 300 mg of sub cutaneous 
dupilumab every 2 weeks or placebo for 24 weeks. Patients 
in SINUS-52 received dupilumab 300 mg every 2 weeks for 
52 weeks, received dupilumab 300 mg every 2 weeks for 
the first 24 weeks followed by extending the treatment 
schedule to dupilumab every 4 weeks until reaching a total 
of 52 weeks, or received placebo throughout. Patients in 
SINUS-24 were followed up during an additional 24 weeks, 
and patients in SINUS-52 were followed up for an 
additional 12 weeks. In SINUS-24, visits were scheduled 
every 2 weeks from randomisation to week 8 and at weeks 
16 and 24, with follow-up visits at week 36 and 48. From 
week 10, home administration of the study drug by patients 
or caregivers occurred every 2 weeks, with optional visits 
for administration scheduled at weeks 10–14 and 18–22. 
CT scans were done at baseline, week 24, and week 48. 
Nasal endoscopy, University of Pennsylvania Smell Identi-
fication Test (UPSIT), 22-item Sino-Nasal Outcome Test 
(SNOT-22), visual analog scale for rhinosinusitis, and 
spirometry and six-item Asthma Control Questionnaire 
(ACQ-6) in patients with asthma were administered at 
weeks 0, 8, 16, 24, and 48. Laboratory tests for biomarkers 
were done at weeks 0 and 24. In SINUS-52, visits were 
scheduled every 2 weeks from randomisation to week 8, 
and at weeks 16, 24, 40, and 52, with a follow-up visit at 
week 64. From week 10, home administration of study 
drug by patients or caregivers occurred every 2 weeks, 
with optional visits for administration scheduled at 
weeks 10–14, 18–22, 26–38, and 42–50. CT scans were done 
at baseline, week 24, and week 52. Nasal endoscopy, 
UPSIT smell test, SNOT-22, and visual analog scale for 
rhinosinusitis were administered at weeks 0, 4, 8, 16, 24, 
40, and 52. Spirometry and ACQ-6 in patients with asthma 
were administered at weeks 0, 4, 16, 24, 40, and 52. 
Laboratory tests for blood biomarkers were done at weeks 
0, 24, and 52 and for nasal secretion biomarkers were 
done at weeks 0 and 24.
Both studies used the Medidata Rave system as the data 
repository for site and patient data. Cognizant Technology 
Solutions did database setup, data reconciliation, and 
data review and cleaning. Data were recorded in source 
documents at the sites for data from electronic case 
report forms or directly in the systems for some external 
data. Investigators approved all electronic case report 
form data by applying electronic signatures directly 
to the system. Once all data were clean and approved 
by the site, the database was extracted and locked, 
and data were transferred to the SAS environment for 
statistical analysis.
Outcomes
The coprimary endpoints in both studies were change 
from baseline in both endoscopic NPS and nasal 
congestion severity (based on monthly average of daily 
score recorded by patients) at week 24. Preplanned sub-
groups for assessing consistency in treatment eﬀects are 
listed in the appendix (pp 9–10).
Key secondary endpoints were change from baseline at 
week 24 in sinus opacification, assessed by Lund-Mackay 
CT score (third coprimary endpoint in Japan); patient-
reported total symptom score (a composite severity 
score consisting of the sum of daily symptoms of nasal 
congestion, loss of smell, and anterior or posterior 
rhinorrhoea); daily loss of smell or smell impairment; 
SNOT-22 score; and UPSIT smell test. Multiplicity-tested 
key secondary endpoints for SINUS-52 were change 
from baseline at week 52 in NPS, nasal congestion, and 
SNOT-22 score (group A alone). NPS and Lund-Mackay 
CT scan scoring was done centrally by masked review of 
the video recordings of standardised endoscopies (for 
NPS) and sinus images (for Lund-Mackay CT).
Data from the two studies were pooled to assess the 
proportion of patients requiring systemic corticosteroids 
or sinonasal surgery (done or planned) during the 
treatment period. Changes from baseline at week 24 
in FEV₁ and ACQ-6 scores were assessed in the pooled 
subset with comorbid asthma.
The proportion of patients with at least a 1-point or 
2-point improvement in NPS score was also reported, 
along with change from baseline in rhinosinusitis 
disease severity assessed by a visual analog scale (score 
0–10 cm, >7 cm indicating severe disease) and peak 
nasal inspiratory flow.
Safety assessments included vital signs, physical exa-
mination, clinical laboratory assessment, 12-lead electro-
cardiogram findings, and incidence of adverse events 
and serious adverse events. For SINUS-52, we also 
assessed changes in blood eosinophil count; serum total 
IgE; thymus and activation-regulated chemokine (TARC; 
also known as C-C motif chemokine 17), peri ostin, and 
plasma eotaxin-3 (also known as C-C motif chemokine 26) 
concentrations; and eosinophil cationic protein (ECP) 
and eotaxin-3 concentrations and total IgE in nasal 
secretions.
Statistical analysis
On the basis of a previous phase 2 study,27 we estimated 
that a sample size of approximately 120 patients per 
treatment group would give the SINUS-24 study 
98% power (two-tailed test at an α level of 0·05) to detect 
an eﬀect size of 0·588 in NPS (on the basis of assumed 
mean diﬀerence of 1·24 and common SD of 2·11), and 
95% power to detect an eﬀect size of 0·534 in nasal 
congestion (on the basis of assumed mean diﬀerence 
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of 0·55 and common SD of 1·03) at week 24 in the 
dupilumab group, with 93% combined power for both 
endpoints, assuming no negative correlation between 
endpoints. SINUS-24 had an equal allocation ratio. 
SINUS-52 had three arms, randomised 1:1:1. The pooling 
of groups A and B for the primary analyses resulted in the 
use of an allocation ratio of 2:1 to assess the sample size. 
The pooling of groups A and B at week 24 (approximately 
240 patients) would give 99% power to detect the same 
eﬀect size as previously described for NPS and nasal 
congestion in patients treated with dupilumab, with 
98% combined power. All sample size calculations were 
done with nQuery Advisor 7.
We did eﬃcacy analyses in the intention-to-treat 
population, defined as all patients who were randomly 
assigned; data were analysed according to assigned 
intervention, whether received or not. Primary and 
key secondary endpoints were prospectively defined, 
multiplicity-adjusted, and analysed with a hybrid of the 
worst observation carried forward (WOCF) and multiple 
imputation methods, followed by an ANCOVA model 
with the baseline value of the corresponding endpoint, 
Figure 1: Patient disposition and trial profile
Some patients who discontinued treatment before week 24 continued to participate in the study, follow-up, or both. SCS=systemic corticosteroid.
133 assigned to placebo 
every 2 weeks 
276 randomly assigned
230 ineligible
506 patients screened
LIBERTY NP SINUS–24 LIBERTY NP SINUS–52
130 completed 24-week study 
period
124 completed study period
133 included in 
intention-to-treat 
population
25 had SCS or surgery 
before week 24
7 discontinued treatment 
before week 24
3 adverse event
1 no treatment eﬃcacy
0 poor compliance
3 other reasons
143 assigned to dupilumab 
every 2 weeks
141 completed 24-week study 
period
138 completed study period
143 included in 
intention-to-treat 
population
153 included in 
intention-to-treat 
population
145 included in 
intention-to-treat 
population
150 included in 
intention-to-treat 
population
10 had SCS or surgery 
before week 24
5 discontinued treatment 
before week 24
5 adverse event
44 had SCS or surgery 
before week 24
19 discontinued treatment 
before week 24
10 adverse event
3 no treatment eﬃcacy
1 poor compliance
5 other reasons
10 had SCS or surgery 
before week 24
3 discontinued treatment 
before week 24
1 no treatment eﬃcacy
2 other reasons
16 had SCS or surgery 
before week 24
7 discontinued treatment 
before week 24
4 adverse event
3 other reasons
153 assigned to placebo 
every 2 weeks
150 assigned to dupilumab 
every 2 weeks
145 assigned to dupilumab 
every 2 weeks until week 24 
and every 4 weeks from 
weeks 24 to 52
66 had SCS or surgery 
before week 52
31 discontinued treatment 
before week 52
16 adverse event
8 no treatment eﬃcacy
1 poor compliance
6 other reasons
9 discontinued study 
before week 48
3 adverse event
6 other reasons
4 discontinued study 
before week 48
2 adverse event
2 other reasons
17 had SCS or surgery 
before week 52
5 discontinued treatment 
before week 52
1 adverse event
2 no treatment eﬃcacy
2 other reasons
22 had SCS or surgery 
before week 52
13 discontinued treatment 
before week 52
6 adverse event
1 no treatment eﬃcacy
6 other reasons
148 completed 24-week study 
period
144 completed 24-week study 
period
147 completed 24-week study 
period
140 completed 52-week study 
period
142 completed 52-week  study 
period
146 completed 52-week  study 
period
448 randomly assigned
358 ineligible
806 patients screened
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treatment, asthma or NSAID-exacerbated respiratory 
disease status, surgery history, and study region as 
covariates. Statistical inference, including the least 
squares means obtained from all 40 imputed data, were 
combined by use of Rubin’s rule.
For patients who underwent nasal polyps surgery or 
received systemic corticosteroids for any reason, data 
collected post-surgery (actual date) or post-systemic 
corticosteroid treatment were set to missing in the WOCF-
multiple imputation approach, and the worst post-baseline 
value on or before the time of surgery or systemic 
corticosteroid treatment was used to impute missing week 
24 or 52 values (depending on the study; baseline values 
were used for patients whose post-baseline values were 
all missing). For patients who discontinued treatment 
without rescue by surgery or systemic corticosteroids, we 
used a multiple imputation approach to impute missing 
values, using all patients who had not been rescued by 
surgery or were not receiving systemic corticosteroids.
We implemented a hierarchical multiplicity procedure 
to control the overall type 1 error rate for testing the 
coprimary and selected key secondary endpoints. 
The overall α was 0·05. We tested comparisons with 
placebo on the basis of a hierarchical order (appendix p 12), 
with two-sided α=0·05. In SINUS-52, groups A and B 
were pooled at week 24 for analysis. At week 52, each 
of the active treatment groups were compared only 
with placebo.
We preplanned a pooled integrated assessment of the 
eﬃcacy data from SINUS-24 and SINUS-52 before the 
LIBERTY NP SINUS-24 LIBERTY NP SINUS-52 Overall population 
(n=724)
Placebo 
(n=133)
Dupilumab, q2w 
(n=143)
Placebo 
(n=153)
Dupilumab, q2w–q4w 
(n=145)
Dupilumab, q2w 
(n=150)
Age (years) 50 (41–60) 52 (39–61) 53 (44–61) 53 (42–63) 51 (42–61) 52 (42–61)
Sex
Men 70 (53%) 88 (62%) 95 (62%) 87 (60%) 97 (65%) 437 (60%)
Women 63 (47%) 55 (38%) 58 (38%) 58 (40%) 53 (35%) 287 (40%)
Body-mass index (kg/m²) 28·36 (5·76) 27·49 (5·11) 27·91 (5·50) 27·96 (5·51) 27·96 (5·53) 27·93 (5·47)
Nasal polyp duration (years) 10·77 (8·57) 11·42 (9·69) 10·88 (9·40) 10·67 (9·12) 11·28 (10·38) 11·01 (9·45)
Nasal polyp surgery
≥1 previous surgery 99 (74%) 99 (69%) 88 (58%) 85 (59%) 88 (59%) 459 (63%)
≥3 previous surgeries 29 (22%) 33 (23%) 18 (12%) 9 (6%) 22 (15%) 111 (15%)
Time since most recent nasal polyp surgery (years) 5·54 (5·07) 5·93 (5·57) 8·77 (7·15) 8·41 (6·83) 7·54 (7·02) 7·16 (6·44)
Systemic corticosteroid use in the preceding 2 years 87 (65%) 92 (64%) 122 (80%) 116 (80%) 121 (81%) 538 (74%)
Bilateral endoscopic nasal polyp score* (scale 0–8) 5·86 (1·31) 5·64 (1·23) 5·96 (1·21) 6·29 (1·20) 6·07 (1·22) 5·97 (1·25)
Nasal congestion or obstruction score* (scale 0–3) 2·45 (0·55) 2·26 (0·57) 2·38 (0·54) 2·44 (0·59) 2·48 (0·62) 2·40 (0·58)
SNOT-22 total score* (scale 0–110) 50·87 (20·22) 48·00 (20·16) 53·48 (21·85) 51·89 (21·05) 50·16 (19·72) 50·94 (20·66)
Smell test (UPSIT) score* (scale 0–40) 14·44 (8·31) 14·68 (8·66) 13·78 (8·31) 13·60 (7·57) 13·46 (8·20) 13·98 (8·21)
Loss-of-smell score* (scale 0–3) 2·73 (0·51) 2·70 (0·57) 2·72 (0·52) 2·73 (0·59) 2·81 (0·46) 2·74 (0·53)
Lund-Mackay CT total score* (scale 0–24) 19·55 (4·26) 18·55 (4·55) 17·65 (3·76) 17·81 (3·89) 18·42 (3·61) 18·37 (4·06)
Rhinosinusitis disease severity* (visual analog 
scale 0–10 cm)
7·96 (2·06) 7·42 (2·01) 7·98 (2·22) 7·78 (2·20) 8·24 (1·77) 7·88 (2·07)
Baseline peak nasal inspiratory flow* (L/min) 83·52 (56·30) 98·59 (56·70) 87·47 (56·14) 84·86 (59·98) 80·96 (50·15) 87·07 (56·08)
Baseline blood eosinophils (× 10⁹ cells per L) 0·44 (0·31) 0·44 (0·35) 0·45 (0·36) 0·40 (0·30) 0·45 (0·39) 0·43 (0·34)
Baseline total IgE (IU/mL) 222·55 (269·11) 202·06 (282·37) 227·80 (267·13) 282·28 (463·72) 210·82 (256·78) 229·21 (318·13)
Baseline eotaxin-3 (pg/mL) 67·36 (73·53) 74·94 (63·36) 90·84 (111·25) 83·36 (164·07) 70·61 (45·16) 77·72 (101·81)
Any type 2 medical history, including asthma or 
NSAID-exacerbated respiratory disease
99 (74%) 109 (76%) 127 (83%) 120 (83%) 122 (81%) 577 (80%)
Asthma 79 (59%) 82 (57%) 91 (59%) 91 (63%) 85 (57%) 428 (59%)
NSAID-exacerbated respiratory disease 38 (29%) 46 (32%) 44 (29%) 41 (28%) 35 (23%) 204 (28%)
Any type 2 medical history, excluding asthma or 
NSAID-exacerbated respiratory disease
75 (56%) 81 (57%) 98 (64%) 99 (68%) 96 (64%) 449 (62%)
Age of onset of asthma in patients with comorbid 
asthma (years)
33·42 (15·42) 38·28 (13·96) 33·29 (16·14) 33·57 (18·18) 35·54 (15·57) 34·78 (16·01)
Data are n (%) or mean (SD), unless otherwise specified. Region was a covariate in these studies and is not reported in this table. Direct statistical comparisons between the groups for demographics and 
characteristics were not prespecified, and therefore were not done. q2w=every 2 weeks. q4w=every 4 weeks. SNOT-22=22-item Sino-Nasal Outcome Test. UPSIT=University of Pennsylvania Smell 
Identification Test. NSAID=non-steroidal anti-inflammatory drug. *Higher scores indicate greater disease severity except for UPSIT and peak nasal inspiratory flow, for which higher scores indicate lower 
disease severity.
Table 1: Patient baseline demographics and clinical characteristics (intention-to-treat population)
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database lock. In this single-stage, fixed-eﬀect individual 
data meta-analysis, we did two multiplicity-adjusted 
analyses: change from baseline at week 24 in FEV₁ and 
proportion of patients requiring systemic corticosteroids 
or nasal polyp surgery (actual or planned) during the 
entire treatment period (dupilumab every 2 weeks and 
placebo) of both studies.
For the pooled analysis of the change from baseline at 
week 24 in FEV₁, all dupilumab groups and placebo 
groups in both studies were pooled at week 24. We 
used the same method of WOCF-multiple imputation 
followed by an ANCOVA model for statistical analysis, 
with an additional covariate of the study indicator in the 
ANCOVA model.
For the proportion of patients requiring systemic 
corticosteroids or nasal polyp surgery (actual or planned) 
during the treatment period, we pooled the entire 
dupilumab every 2 weeks treatment period (group A up 
to 52 weeks and B up to 24 weeks from SINUS-52 and 
the dupilumab group from SINUS-24) from both 
studies, and we included a forced censor for the 
SINUS-52 group B at week 24. The entire placebo 
treatment period, of up to 52 weeks for SINUS-52 and 
up to 24 weeks for SINUS-24, was pooled as well. The 
probability that a patient in each treatment group would 
require rescue at week 52 was determined with the Cox 
proportional hazards model and the Kaplan-Meier 
method. The Cox model used the event as the dependent 
variable and the study indicator, treatment group, 
asthma or NSAID-exacerbated respiratory disease strata, 
previous surgery strata, and study region as covariates. 
We estimated hazard ratios (HRs) and corresponding 
95% CIs and p values for dupilumab every 2 weeks 
versus placebo. We used a Kaplan-Meier curve to derive 
the probability that a patient would have an event up to 
week 52, with point probabilities and corresponding 
95% CIs calculated.
We planned a pooled integrated assessment of the safety 
adverse event data from SINUS-24 and SINUS-52, 
focusing on the first 24 weeks of treatment, combining 
both dupilumab groups in SINUS-52 up to week 24 with 
the dupilumab group in SINUS-24 and the placebo groups 
in both studies until week 24. The safety population was 
defined as all patients exposed to the investigational 
medicinal product, regardless of the amount of exposure. 
We assessed long-term safety up to week 52 of treatment 
in SINUS-52.
An independent data monitoring committee reviewed 
safety data throughout the trial, meeting every 3 to 
6 months. These trials are registered at Clinicaltrials.gov, 
NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52). 
We used SAS, version 9.4, for statistical analyses. The 
appendix (pp 9–10) gives further details of these analyses.
Role of the funding source
The external authors and study sponsors participated 
in the study design, data collection, data analysis, data 
interpretation, and development of the report, and gave 
approval to submit for publication. The corresponding 
author had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between Dec 5, 2016, and Aug 3, 2017, patients were 
enrolled in SINUS-24, with 276 patients randomly 
assigned to dupilumab every 2 weeks (n=143) or placebo 
(n=133; figure 1). The final patient treatment was done 
on July 5, 2018. Between Nov 28, 2016, and Aug 28, 2017, 
patients were enrolled in SINUS-52, with 448 patients 
randomly assigned to placebo (n=153), dupilumab every 
2 weeks (n=150), or dupilumab every 2 weeks until 
week 24 and every 4 weeks until week 52 (n=145; 
figure 1). The final patient treatment was done on 
Aug 29, 2018. Both trials were unmasked simulta-
neously once the SINUS-52 treatment period and 
SINUS-24 study were completed.
In SINUS-24, 12 (4%) of 276 patients discontinued 
treatment before week 24, and 13 (5%) patients discon-
tinued from the study; one patient was randomly assigned, 
but not treated, and the primary reason for discontinuation 
was occurrence of adverse events (figure 1). In SINUS-52, 
29 (6%) of 448 patients discontinued before week 24, 
and 49 (11%) patients discontinued treatment before 
Figure 2: Change from baseline over time in nasal polyp score (A) and nasal congestion or obstruction (B) in 
SINUS-24 and SINUS-52
Error bars denote SE. LS=least squares. *p<0·0001.
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week 52; one patient was randomly assigned, but not 
treated. Occurrence of adverse events was the most 
common reason for treatment discon tinuation (figure 1).
Baseline demographics and characteristics were 
balanced across the treatment groups within each 
study and across both studies and were consistent with a 
population with severe, inadequately controlled CRSwNP, 
on the basis of the ubiquity of chronic rhinosinusitis 
symptoms, bilateral obstructive polyps, and extensive 
involvement of the sinuses (table 1). Most patients 
(705 [97%] of 724) had either previously received systemic 
corticosteroids (64–81%) or sinonasal surgery (58–74%). 
Approximately 551 (76%) of 724 patients had anosmia 
at baseline, 428 (59%) had comorbid asthma, and 
204 (28%) had NSAID-exacer bated respiratory disease. 
Mean baseline FEV1 in patients with asthma was 2·61 L 
(percent predicted 84% [18·70]) and ACQ-6 score 
was 1·59, suggesting inadequately controlled asthma. 
Most patients (388 [91%] of 427) in this subgroup had 
received asthma medi cations, primarily inhaled cortico-
steroids and long-acting β-agonists (282 [74%] of 382), in 
the preceding year.
The improvement in endoscopic NPS at week 24 was 
significantly greater with dupilumab treatment than with 
placebo in both studies (figure 2, table 2). In the placebo 
group treated with standard of care, NPS worsened at 
week 24 and week 52. Dupilumab treatment also sig-
nificantly improved patient-reported nasal congestion 
scores compared with placebo (figure 2, table 2). We 
observed improvements in NPS and nasal congestion as 
early as the first assessment timepoint after the start of 
dupilumab treatment (within the first 4 to 8 weeks), 
with continued improvement evident up to the end of 
treatment in both studies.
We also observed improvements in NPS and nasal 
congestion in patient subgroups with comorbid asthma, 
NSAID-exacerbated respiratory disease, or previous 
surgery (appendix pp 25–27). The proportion of patients 
achieving at least a 2-point improvement in NPS at week 
24 was higher with dupilumab (66 [46%] of 143 patients 
in SINUS-24, and 136 [46%] of 295 patients with 
SINUS-52) than with placebo (6 [5%] of 133 patients in 
SINUS-24, and 1 [1%] of 153 in SINUS-52; appendix p 28).
All multiplicity-adjusted key secondary endpoints 
showed significant and clinically relevant improvements 
with dupilumab treatment (p<0·0001 in both studies; 
table 2, appendix pp 13–14), with all eﬀects having an 
early onset (in the first 2 to 4 weeks of treatment). 
The magnitude of improvements in patient subgroups 
with comorbid asthma, NSAID-exacerbated respira tory 
disease, or previous surgery was similar to that of 
improvements in the overall treatment population. 
Patients treated with dupilumab in SINUS-52 had 
progressive improvement up to week 52 (figure 2, table 2, 
appendix pp 13–14), whereas symptoms worsened after 
discontinuation of dupilumab at week 24 in patients in 
SINUS-24.
Lund-Mackay CT scores improved significantly in 
dupilumab groups at week 24 compared with those of 
placebo groups (table 2, appendix p 13), with improve-
ments seen in all sinuses (appendix p 15). Patients with 
comorbid asthma, NSAID-exacerbated respiratory dis-
ease, or previous surgery showed similar improve ments 
(appendix pp 25–27). Improvements in SNOT-22 scores 
with dupilumab treatment exceeded the minimal clinically 
important diﬀerence of an 8·9-point improvement or 
higher28 and were significant compared with those with 
placebo (table 2, appendix p 13). Results of the UPSIT 
smell test showed that the proportion of patients with 
anosmia (UPSIT score of ≤18) in the dupilumab groups 
decreased in SINUS-24 from 104 (74%) of 140 patients 
at baseline to 33 (24%) of 138 at week 24 and in 
SINUS-52 from 228 (79%) of 287 patients to 84 (30%) of 
280 at week 24, with almost no change observed in 
the placebo group (appendix p 29). Patients treated with 
dupilumab in both studies had a substantial reduction 
in rhinosinusitis disease severity assessed with visual 
analog scale and improvement in peak nasal inspiratory 
flow and rhinorrhoea daily symptom score at week 24 
(prespecified secondary analyses; appendix p 30).
The magnitude of additional improvements observed 
for NPS and Lund-Mackay CT scan scores from week 24 
to week 52 in SINUS-52 were numerically greater in 
patients who continued the dupilumab every 2 weeks 
regimen (group A) than in those who switched to a dose 
every 4 weeks (group B; NPS: −0·53 for group A and 
−0·31 for group B; Lund-Mackay CT scan score −1·37 for 
group A and −0·62 for group B). Additional improve-
ments for nasal congestion and the other secondary 
endpoints from week 24 to week 52 were similar 
between groups (appendix p 31).
In a prespecified pooled analysis, the proportion of 
patients who received treatment with systemic cortico-
steroids or eﬀectively underwent sinonasal surgery during 
Figure 3: Time to first systemic corticosteroid use or nasal polyp surgery during the treatment period in the 
pooled analysis of SINUS-24 and SINUS-52
HR=hazard ratio.
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the treatment period was significantly lower in the pooled 
dupilumab every 2 weeks group than in the pooled placebo 
group (figure 3). This reduction reflects the reductions 
seen in the separate HRs for patients who received systemic 
corticosteroids (74% lower in the dupilumab group than 
in placebo) and surgery (83% lower in the dupilumab 
group than in placebo; appendix p 32).
In prespecified analyses of the pooled subset of 
patients with comorbid asthma (258 in the dupilumab 
group and 170 in the placebo group) at week 24, dupilumab 
significantly improved lung function (assessed with 
FEV₁ in a multiplicity-controlled analysis) and asthma 
control (assessed with ACQ-6) compared with placebo 
(table 3). Median baseline eosinophil count in patients 
with comorbid asthma was 0·43 × 10⁹ cells per L 
(IQR 0·26–0·65). Improvements in lung function and 
asthma control were similar in patients with comorbid 
asthma with high (≥0·3 × 10⁹ cells per L) and low 
(<0·3 × 10⁹ cells per L) baseline blood eosinophil counts 
(appendix pp 33–34). Prespecified exploratory analyses 
of biomarkers in patients treated with dupilumab in 
SINUS-52 showed a consistent decrease in concen-
trations of serum total IgE, periostin, TARC, and plasma 
eotaxin-3 at weeks 24 and 52 and in concentrations of 
ECP, total IgE, eotaxin-3, and IL-5 in nasal secretions at 
week 24. In both studies, and consistent with previous 
dupilumab studies, we observed a transient, but not 
significant, increase in mean (but not median) blood 
eosinophil counts in patients treated with dupilumab. In 
SINUS-52, eosinophil counts returned to baseline levels 
by the end of the 52-week treatment period (appendix 
pp 35–37).
Results of post-hoc analysis that excluded patients with 
major or crucial deviations potentially aﬀecting eﬃcacy 
analyses were consistent with the primary analysis 
(appendix pp 20–23). Sensitivity analyses including 
as-observed analysis (accounting for all post-systemic 
corticosteroid data in patients who received systemic 
corticosteroids for any reason) done in the intention-to-
treat population in both studies supported the robustness 
of the results (appendix p 24).
In the pooled safety population, the incidence of 
adverse events emerging during the 24-week treatment 
period was lower in the dupilumab group than in the 
placebo group (table 4). The most commonly reported 
adverse events were nasopharyngitis, nasal polyps 
(worsening nasal polyps, need for nasal polyp surgery or 
systemic corticosteroids, or both), headache, asthma 
(worsening of asthma), epistaxis, and injection-site 
erythema; these events were more frequent with placebo 
Testing 
hierarchy 
position
Pooled 
placebo 
(n=286)
Pooled 
dupilumab 
q2w (n=438)
HR vs placebo (95% CI; 
p value)
Pooled placebo with 
comorbid asthma (n=170)
Pooled dupilumab q2w with comorbid asthma 
(n=258)
Week 24 
mean (SD)
LS mean 
change from 
baseline at 
week 24 (SE)
Week 24 
mean (SD)
LS mean 
change from 
baseline at 
week 24 (SE)
LS mean diﬀerence vs 
placebo (95% CI; 
p value)
Prespecified pooled analysis
Patients requiring rescue with systemic 
corticosteroids or nasal polyp surgery 
(n [%])
10 97 (34%) 42 (10%) 0·243 (0·169 to 0·351; 
p<0·0001)
·· ·· ·· ·· ··
Total patient-years followed up (years) ·· 208·4 280·1 ·· ·· ·· ·· ·· ··
Prespecified pooled asthma analyses
FEV₁ (L) 11 ·· ·· ·· 2·57 (0·80) –0·07 (0·04) 2·76 (0·91) 0·14 (0·03) 0·21 (0·13 to 0·29; 
p<0·0001)
ACQ-6 (scale 0–6)  ·· ·· ·· ·· 1·52 (1·11) –0·02 (0·07) 0·70 (0·82) –0·84 (0·06) –0·82 (–0·98 to –0·67; 
p<0·0001)
On the basis of published thresholds for clinical meaningfulness for ACQ-6,29 changes in the outcome can be considered clinically meaningful. Comparisons of dupilumab versus placebo for endpoints from 
outside the testing hierarchy are shown with 95% CI. q2w=every 2 weeks. HR=hazard ratio. LS=least squares. FEV1=forced expiratory volume in 1 s. ACQ-6=six-item Asthma Control Questionnaire.
Table 3: Prespecified eﬃcacy endpoints in the pooled SINUS-24 and SINUS-52 population
Placebo 
(n=282)
Dupilumab 
q2w 
(n=440)
Risk diﬀerence 
(% [95% CI]) dupilumab 
q2w vs placebo
Treatment-emergent adverse events
Any 208 (74%) 305 (69%) −6·48 (−13·04 to 0·08)
Any serious 16 (6%) 15 (3%) −2·80 (−6·30 to 0·70)
Any leading to death 0 0 0
Any leading to permanent treatment discontinuation 15 (5%) 11 (3%) −2·66 (−6·01 to 0·69)
Treatment-emergent adverse events occurring in ≥5% of patients*
Asthma 20 (7%) 7 (2%) ··
Epistaxis 20 (7%) 25 (6%) ··
Headache 24 (9%) 32 (7%) ··
Injection-site erythema† 22 (8%) 28 (6%) ··
Nasal polyps 33 (12%) 12 (3%) ··
Nasopharyngitis 41 (15%) 55 (13%) ··
Data are n (%) unless otherwise specified. q2w=every 2 weeks. *According to the preferred terms of the Medical 
Dictionary for Regulatory Activities; asthma refers to a worsening of asthma, and nasal polyps refers to a worsening of 
nasal polyps leading to surgery or systemic corticosteroid use. †Injection-site reaction was a prespecified adverse event 
of interest in the protocol.
Table 4: Adverse events that emerged during the intervention period (pooled safety population at week 24)
Articles
1648 www.thelancet.com   Vol 394   November 2, 2019
than with dupilumab (table 4, appendix pp 38–39). Over 
the 52-week period in SINUS-52, incidences of cough, 
bronchitis, arthralgia, accidental overdose, and injection-
site reactions were slightly more frequent in the two 
dupilumab groups than in placebo (appendix pp 40–41). 
Treatment-emergent adverse events of worsening of 
nasal polyps and asthma and of sinusitis, arthralgia, and 
accidental overdose occurred more frequently in patients 
who switched from dupilumab every 2 weeks to every 
4 weeks than in those who remained on dupilumab every 
2 weeks for the full 52 weeks (appendix pp 40–41).
In the pooled 24-week safety population, serious 
adverse events were more common in the placebo group 
than in the dupilumab group (table 4). Two deaths 
occurred during the study period that were deemed 
unrelated to the study drug: one patient given placebo in 
SINUS-24 had suspected acute myocardial infarction 
occurring after the period of treatment-emergent adverse 
events, and one treated with dupilumab in SINUS-52 had 
intracranial haemorrhage after a fall, occurring within 
the period of treatment-emergent adverse events. 
Conjunctivitis was reported in seven patients receiving 
dupilumab and in one patient receiving placebo; 
none of these cases were serious, severe, or associated 
with treatment discontinuation. Four patients had 
eosinophilia with clinical symptoms reported as 
treatment-emergent adverse events: one patient had 
eosinophilic granulomatosis with polyangiitis (EGPA) 
during treatment with dupilumab; one had eosinophilia 
associated with arthralgia, asthma exacerbation, and 
insomnia during dupilumab treatment; one had EGPA 
more than 300 days after a single dupilumab dose; and 
one had EGPA while receiving placebo. Further adverse 
event data can be found in the appendix (pp 42–55).
Discussion
Patients with CRSwNP generally have a high symptom 
burden, including anosmia, high polyp recurrence rates, 
asthma comorbidity, and poor health-related quality of 
life. In patients with severe CRSwNP inadequately 
controlled with standard of care, adding dupilumab to 
daily MFNS provided early, significant, and clinically 
meaningful improvements across all aspects of disease, 
including a reduction in systemic corticosteroid treat-
ment and surgery. This broad and significant eﬀect was 
reflected in reduced polyp size and disease in all sinuses, 
and relief in major symptoms of CRSwNP (nasal 
congestion, loss of smell, and rhinorrhoea). In patients 
with comorbid asthma, regardless of baseline eosinophil 
count, dupilumab treatment improved lung function 
and asthma control. In SINUS-24, treatment eﬀects 
diminished after dupilumab discontinuation, whereas 
in SINUS-52, treatment eﬀects continued to improve up 
to week 52, underscoring the need for continued 
suppression of type 2 inflammation for sustained disease 
control. The magnitude of the additional reductions 
in nasal polyp size and sinus disease observed from 
week 24 to week 52 in SINUS-52 was greater in patients 
who received dupilumab every 2 weeks for 52 weeks than 
in those who switched to dupilumab every 4 weeks after 
week 24. In patients in the placebo groups who received 
daily MFNS alone, no meaningful improvements were 
noted in polyp size, CT scan score, or sense of smell.
The existing treatment approach for severe CRSwNP 
is characterised by continuous topical and repeated 
systemic corticosteroid use and surgery, resulting in 
high risk for morbidity, poor health-related quality of 
life, and sig nificant economic burden.15,17,30 The goals of 
CRSwNP treatment are to achieve eﬀective and sustained 
symptom control, minimise recurrence of polyps, and 
attain better control of comorbid lower airway disease 
while minimising the risk of side-eﬀects associated with 
systemic corticosteroid use and repeated sinus surgery. 
Almost all patients (97%) in SINUS-24 and SINUS-52 had 
received systemic corticosteroids or sinonasal surgery 
before entering the studies. Compared with placebo, 
dupilumab treatment greatly reduced the use of systemic 
corticosteroids and the proportion of patients who had 
sinonasal surgery in the prespecified pooled analyses. 
Dupilumab also improved symptoms and health-related 
quality of life, as reflected by an improvement in 
SNOT-22 scores that largely exceeded the threshold for a 
clinically relevant change.28 Impairment of the sense of 
smell, one of the most troublesome symptoms in 
patients with CRSwNP, correlates with disease severity 
and recurrence and has a substantial eﬀect on health-
related quality of life.5,6 Approximately 75% of patients in 
SINUS-24 and SINUS-52 had anosmia at baseline, 
whereas only 24–30% had anosmia after dupilumab 
treatment; no change was observed in the placebo 
groups.
Of importance, the eﬃcacy of dupilumab was shown 
both in the overall population and in subgroups with 
higher disease burden that is diﬃcult to control, such as 
patients with comorbid asthma, NSAID-exacerbated 
respiratory disease, or previous sinonasal surgery. In 
patients with CRSwNP and comorbid asthma, dupilumab 
not only improved upper airway outcome measures, but 
also significantly improved lung function and achieved 
better asthma control, whereas patients in the placebo 
groups showed little or no improvement despite use of 
asthma medication, including inhaled therapies. Patients 
with CRSwNP have been noted in the literature to have 
a predominant type 2 endotype.9,10 The robust FEV₁ 
improvement after dupilumab treatment in patients with 
CRSwNP and asthma, regardless of baseline eosinophil 
count, supports this finding and suggests that blood 
eosinophils provide no further specificity in identifying 
dupilumab responsiveness in this population. This 
concomitant benefit for lower airway disease highlights 
the value of a therapy that can simultaneously address 
multiple comorbid manifestations of type 2 inflammatory 
diseases in the upper and lower airways. Dupilumab was 
generally well tolerated and had an acceptable safety 
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profile for the treatment of patients with severe CRSwNP. 
One patient had EGPA while being treated with 
dupilumab, and two patients in placebo groups had EGPA 
in the context of steroid withdrawal; the causal relation-
ship of EGPA with dupilumab has not been established.
The reductions in type 2 biomarkers in serum 
(total IgE, TARC, eotaxin-3, and periostin) and in nasal 
secretions (ECP, eotaxin-3, and total IgE) observed in 
these studies were consistent with the method of action 
of dupilumab and with previous dupilumab studies in 
asthma and atopic dermatitis. The transient increase in 
the blood eosinophil counts observed in both studies is 
consistent with the hypothesis that dupilumab blocks 
eosinophil tissue migration by inhibiting the production 
of eotaxins mediated by IL-4 and IL-13 (supported by an 
observed reduction of eotaxin-3 concentrations in the 
serum and in the target organ [nasal secretion]), but not 
the production of eosinophils or egress from bone mar-
row. This mechanism results in the observed transient 
increase in circulating eosinophils, consistent with other 
clinical studies of dupilumab.
Our studies had some limitations. The treatment eﬀects 
showed progressive improvement during the randomised 
treatment period, and maximum eﬀects were not reached 
at week 52 in SINUS-52, therefore it is not clear what the 
full treatment eﬀect of dupilumab might be beyond 
52 weeks. We also did not assess dupilumab eﬃcacy as a 
monotherapy without background MFNS treatment.
These data support the benefits of adding dupilumab 
to daily standard of care in patients with CRSwNP as 
a novel approach in treating the entire spectrum of 
clinical manifestations of the disease, a predominantly 
type 2 inflammatory condition, as well as the frequently 
associated type 2 lower airway comorbidities. Dupilumab 
treatment also resulted in substantial reductions in the 
need for systemic corticosteroids and surgery, oﬀering an 
eﬃcacious treatment for patients with severe CRSwNP 
who otherwise have few therapeutic options.
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